Back
Business

CSL Lowers FY26 Guidance, Reports Profit Decline Amid Asset Impairments and Leadership Changes

Generated on: Last updated: 2 sources
View source

CSL Ltd Slashes FY26 Outlook, Reports 80% Profit Drop

"Our growth initiatives are working, but the financial benefits will take longer than previously anticipated to materialise."
— Interim CEO Gordon Naylor

CSL Ltd (ASX: CSL) has revised its financial outlook for fiscal year 2026, citing delayed returns from growth initiatives, and reported a significant decline in statutory profit for the first half of fiscal 2025. The company is also undergoing leadership transitions and implementing a restructuring program.

Financial Updates and Guidance

CSL provided an update from an interim CEO review, projecting FY26 revenue of approximately $15.2 billion on a constant currency basis. The company forecasts FY26 net profit after tax and amortization (NPATA), excluding restructuring costs and impairments, to be approximately $3.1 billion.

The company expects to record additional non-cash, pre-tax asset impairments of approximately $5 billion across FY26 and FY27. These impairments are primarily related to CSL Vifor intangibles and under-used assets. For the full fiscal year, CSL anticipates booking approximately US$1.1 billion in after-tax, non-restructuring impairments, with most of this amount already recognized.

For the half-year ending December 31, 2025, statutory profit decreased by 80% to $US401 million. Under an alternative measure that excludes amortization of acquired intellectual property and significant non-recurring items, underlying profit decreased by 6% to $US1.95 billion. Total revenue for the first half decreased by 4% to $US8.33 billion.

Segment Performance

CSL Behring, the core plasma unit, reported revenue of $US5.5 billion for the first half, a 7% decrease. This decline was influenced by a 6% fall in immunoglobulin sales and a 27% fall in albumin sales.

Specific Headwinds Identified for FY26:

  • $300 million expected decline in US Immunoglobulin revenue due to inventory normalization
  • $200 million revenue decline in Albumin in China due to a market value decline, despite increases in volume and market share
  • Approximately $150 million impact from other factors, including the Middle East conflict and product competition

Restructuring and Cost Savings

CSL is undertaking a transformation and efficiency program targeting $500–$550 million in annual savings by FY28. The company reported it has achieved approximately 60% of its targeted cost savings for fiscal 2026.

These savings are attributed to:

  • Reductions in fixed research costs
  • Lower infrastructure spending
  • Integration of its Behring and Vifor commercial and medical teams

Restructuring efforts incurred costs in the first half.

Leadership and Market Context

A global search for a permanent CEO is underway. Diego Sacristan is scheduled to take over commercial leadership from 1 July 2026. The company's previous CEO, Paul McKenzie, was replaced.

Ken Lim, CSL's chief financial officer, expressed dissatisfaction with the company's performance and indicated that initiatives have been implemented to drive stronger growth.

CSL shares have declined 49% over the past 12 months, compared to a 6% rise in the S&P/ASX 200 Index over the same period.

The company declared an interim dividend of $US1.30 per share, unchanged from the previous year. CSL reaffirmed its fiscal 2026 forecast, projecting modest revenue growth and a return to mid-single-digit growth in underlying profit, excluding one-off restructuring costs and impairments.